Metabolite of quetiapine

Details for Australian Patent Application No. 2004253334 (hide)

Owner AstraZeneca AB

Inventors Not given

Agent Phillips Ormonde Fitzpatrick

Pub. Number AU-A-2004253334

PCT Pub. Number WO2005/002586

Priority 60/484,365 02.07.03 US

Filing date 28 June 2004

Wipo publication date 13 January 2005

International Classifications

A61K 31/554 (2006.01) - having at least one nitrogen and at least one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem

A61P 25/18 (2006.01) Drugs for disorders of the nervous system

Event Publications

19 January 2006 PCT application entered the National Phase

  PCT publication WO2005/002586 Priority application(s): WO2005/002586

3 July 2008 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(e). Examination has been requested or an examination report has issued for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004253337-Use of roscovitine for treating lymphocytic leukemia

2004253333-Dispensing device